ProPhase Labs, Inc. (PRPH) |
| 0.08 -0.01 (-11.11%) 06-12 16:00 |
| Open: | 0.095 |
| High: | 0.095 |
| Low: | 0.0723 |
| Volume: | 93,825 |
| Market Cap: | 0(M) |
| PE Ratio: | -0.03 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 0.15 |
| Resistance 1: | 0.12 |
| Pivot price: | 0.11 |
| Support 1: | 0.07 |
| Support 2: | 0.06 |
| 52w High: | 6.7 |
| 52w Low: | 0.07 |
ProPhase Labs, Inc., founded in 1989 in Garden City, New York (and previously known as The Quigley Corporation), operates as a diversified company with two main areas of focus: Consumer Products and Diagnostic Services. Through its Consumer Products division, ProPhase Labs is actively involved in the entire process—from researching and developing to manufacturing, distributing, marketing, and selling—a range of over-the-counter (OTC) healthcare items and nutritional supplements within the United States. Notable offerings include dietary supplements like Legendz XL, which supports male sexual health, and Triple Edge XL, formulated to enhance energy and stamina. The Diagnostic Services segment provides crucial testing solutions, including PCR tests for SARS-CoV-2 (COVID-19) and its variant mutations, using both saliva and nasal swab collection methods. This segment also offers molecular testing for other respiratory pathogens and supplies personal genomics products and services. Additionally, ProPhase Labs extends its capabilities by providing comprehensive contract manufacturing services, covering product development, pre-commercialization activities, production, warehousing, and distribution. The company's diverse products and services reach consumers through a broad network of national chain drug stores, various regional retailers, and online platforms.
| EPS | -19.800 |
| Book Value | 0.550 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.409 |
| Profit Margin (%) | -272.49 |
| Operating Margin (%) | -330.25 |
| Return on Assets (ttm) | -16.6 |
| Return on Equity (ttm) | -359.1 |
Mon, 01 Jun 2026
ProPhase Labs, Inc. FY 2025: Revenue $4.35M, EPS ($1.74) — 10-K Summary - TradingView
Mon, 01 Jun 2026
[10-K] ProPhase Labs, Inc. Files Annual Report - Stock Titan
Mon, 25 May 2026
PRPH | PROPHASE LABS INC Insider Trading - Quiver Quantitative
Fri, 15 May 2026
ProPhase Labs (NASDAQ: PRPH) delays Q1 2026 10-Q amid 2025 audit - Stock Titan
Wed, 15 Apr 2026
ProPhase Labs Reports Year-End 2025 Results, Highlights - GlobeNewswire
Wed, 15 Apr 2026
$201M in medical claims could start generating cash for ProPhase in Q3 - Stock Titan
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |